PMID- 23380506
OWN - NLM
STAT- MEDLINE
DCOM- 20130930
LR  - 20220310
IS  - 1768-3122 (Electronic)
IS  - 0248-8663 (Linking)
VI  - 34
IP  - 4
DP  - 2013 Apr
TI  - [Management of angiotensin-converting enzyme inhibitor-related angioedema: 
      recommendations from the French National Center for Angioedema].
PG  - 209-13
LID - S0248-8663(12)01195-2 [pii]
LID - 10.1016/j.revmed.2012.12.017 [doi]
AB  - Angiotensin-converting enzyme (ACE) inhibitor-related angioedema (AE) may be 
      fatal in the absence of specific treatment. No consensus for this side effect 
      currently exists. Also, the French national reference centre for angioedema 
      (CREAK) decided to establish recommendations, developed by an expert group and 
      proposed at a national meeting. A scientific committee conducted a comprehensive 
      literature review and worked out with proposals. These proposals were submitted 
      to a vote to the expert panel of CREAK at a national meeting. Proposals that had 
      received the majority were retained. Diagnosis of ACE inhibitor-related AE is 
      based on clinical events. Regarding the severity of the disease, this diagnosis 
      has to be put forward in any patient currently treated with or who has been 
      treated with ACE inhibitors in the previous 6 months. The diagnosis is important 
      because AE does not respond to usual treatment of histamine-induced AE 
      (antihistamines, corticosteroids, and epinephrine), but only to specific 
      treatment of bradykinin-induced AE, as antagonists of bradykinin or concentrates 
      of C1 inhibitor. The subsequent use of ACE is strictly contra-indicated. A report 
      to pharmacovigilance centres of every case is essential. These recommendations 
      should improve the standardization of the management of ACE inhibitor-related AE.
CI  - Copyright (c) 2013 Societe nationale francaise de medecine interne (SNFMI). 
      Published by Elsevier SAS. All rights reserved.
FAU - Nosbaum, A
AU  - Nosbaum A
AD  - Allergologie et immunologie clinique, centre hospitalier Lyon-Sud, hospices 
      civils de Lyon, 69495 Pierre-Benite, France.
FAU - Bouillet, L
AU  - Bouillet L
FAU - Floccard, B
AU  - Floccard B
FAU - Javaud, N
AU  - Javaud N
FAU - Launay, D
AU  - Launay D
FAU - Boccon-Gibod, I
AU  - Boccon-Gibod I
FAU - Fain, O
AU  - Fain O
CN  - Groupe d'experts du CREAK
CN  - French National Center for Angioedema
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Practice Guideline
PT  - Review
TT  - Prise en charge des angioedemes induits par les inhibiteurs de l'enzyme de 
      conversion de l'angiotensine : recommandations du Centre de reference national 
      des angioedemes.
DEP - 20130204
PL  - France
TA  - Rev Med Interne
JT  - La Revue de medecine interne
JID - 8101383
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Angiotensin Receptor Antagonists)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Bradykinin Receptor Antagonists)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Immunosuppressive Agents)
RN  - 7PG89G35Q7 (icatibant)
RN  - S8TIM42R2W (Bradykinin)
SB  - IM
MH  - Adrenergic beta-Antagonists/therapeutic use
MH  - Angioedema/*chemically induced/diagnosis/*drug therapy
MH  - Angiotensin Receptor Antagonists/therapeutic use
MH  - Angiotensin-Converting Enzyme Inhibitors/*adverse effects
MH  - Bradykinin/analogs & derivatives/metabolism/therapeutic use
MH  - Bradykinin Receptor Antagonists
MH  - Dipeptidyl-Peptidase IV Inhibitors/adverse effects
MH  - France
MH  - Humans
MH  - Immunosuppressive Agents/adverse effects
EDAT- 2013/02/06 06:00
MHDA- 2013/10/01 06:00
CRDT- 2013/02/06 06:00
PHST- 2012/12/10 00:00 [received]
PHST- 2012/12/20 00:00 [accepted]
PHST- 2013/02/06 06:00 [entrez]
PHST- 2013/02/06 06:00 [pubmed]
PHST- 2013/10/01 06:00 [medline]
AID - S0248-8663(12)01195-2 [pii]
AID - 10.1016/j.revmed.2012.12.017 [doi]
PST - ppublish
SO  - Rev Med Interne. 2013 Apr;34(4):209-13. doi: 10.1016/j.revmed.2012.12.017. Epub 
      2013 Feb 4.